I agree with Waynesworld, that PYC has the potential to be a very successful compny. IMHO Investors should not expect to see steady increase in revenue/profits for this company.(unlike regular companies) For PYC, revenue will come in spurts, for it requires only one contract to cover a year's costs. The key to success for this company, is to remain cash positive until such time, that it strikes it BIG. The current management is trying to do exactly that, by creating more revenue opportunities to remain cash positive. We d'ont know when it will stike it real big, so we must hold on, and be patient. Sooner or later, it is bound to happen, that a drug using PYC's partnership is on the market. When that happens, you would have wanted to be invested in PYC before the trading halt comes. Surely, the likes of ROCHE, PFIZER, CAMBRIDGE UNIVERSITY believe strongly in the future prospects of PYC and they have invested in PYC in cash or kind to re-enforce this. IMHO we should acknowledge this fact, and be patient, support the management.
PYC Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)